← Back to patent-cliff list
Praziquantel paediatric formulation (Pediatric Praziquantel Consortium)
Tier C — Watch / tradePraziquantel paediatric formulation (Pediatric Praziquantel Consortium)
Pediatric Praziquantel Consortium
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CYP11B1
Indications (approved)：血吸虫病
Regional status
US
-
EU
No progress
2016-06-12
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Praziquantel paediatric formulation (Pediatric Praziquantel Consortium)?
Approved indications include: 血吸虫病.
When does the Praziquantel paediatric formulation (Pediatric Praziquantel Consortium) patent expire?
No public expiry year is available for Praziquantel paediatric formulation (Pediatric Praziquantel Consortium) yet; this page updates once verified.
How do I get a quote for Praziquantel paediatric formulation (Pediatric Praziquantel Consortium) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07